XOMA Corp - Company Profile

Powered by

All the data and insights you need on XOMA Corp in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date XOMA Corp Strategy Report

  • Understand XOMA Corp position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

XOMA Corp: Overview

Select Item

XOMA Corp (Xoma), formerly Xoma Ltd, is a biopharmaceutical company. It develops antibody-based therapeutics. Its lead product, Gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include RZ358, TAK-079, AZD2936 and PTH1R. XOMA X358 is a human negative allosteric modulating insulin receptor antibody. Xoma has a developed proprietary antibody platform, optimization and development technologies, comprising ADAPT, ModulX and OptimX. It operates through its subsidiaries in Bermuda, Ireland, and the US. Xoma is headquartered in Berkeley, California, the US.

 Gain a 360-degree view of XOMA Corp and make more informed decisions for your business Gain a 360-degree view of XOMA Corp and make more informed decisions for your business Find out more
Headquarters United States of America
Address Suite 310, 2200 Powell Street, Emeryville, California, 94608
Website www.xoma.com
Telephone 1 510 2047239
No of Employees 12
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange XOMA (NASD)
Revenue (2022) $6.0M -84.2% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -208.3% (2022 vs 2021)
Market Cap* $176.7M
Net Profit Margin (2022) XYZ -785.5% (2022 vs 2021)
* As of and is in US$
View XOMA Corp financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

XOMA Corp premium industry data and analytics

50+

Clinical Trials

Determine XOMA Corp go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

40+

Pipeline Drugs

Identify which of XOMA Corp’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for XOMA Corp’s relevant decision makers and contact details.

14+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

4

Catalyst Calendar

Proactively evaluate XOMA Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on XOMA Corp’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Pipeline OptimX
TAK-079 ModulX
TAK-169 ADAPT
XYZ
XYZ
XYZ
Understand XOMA Corp portfolio and identify potential areas for collaboration Understand XOMA Corp portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Asset Purchase In June, the company acquired the royalty and milestone rights associated with two assets from LadRx Corporation, arimoclomol, an oral therapeutic for Niemann-Pick disease type C, and aldoxorubicin, an albumin-linked formulation of doxorubicin.
2023 Acquisitions/Mergers/Takeovers In March, the company acquired the commercial payment and a portion of the milestone rights to IXINITY.
2023 Contracts/Agreements In January, the company entered into a research and licensing agreement with Amolyt Pharma to advance pre-clinical development of anti-PTHR1 monoclonal antibodies.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters XOMA Corp Emergent BioSolutions Inc EyePoint Pharmaceuticals Inc Precigen Inc Soligenix Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Emeryville Gaithersburg Watertown Germantown Princeton
State/Province California Maryland Massachusetts Maryland New Jersey
No. of Employees 12 2,500 144 209 13
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Owen Hughes Chairman Executive Board 2023 48
Thomas Burns Senior Vice President - Finance; Chief Financial Officer Senior Management 2017 49
Brad Sitko Chief Investment Officer Senior Management 2023 42
Heather L. Franklin Director Non Executive Board 2021 57
W. Denman Van Ness Director Non Executive Board 2021 80
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Gain insight into XOMA Corp key executives to enhance your sales strategy Gain insight into XOMA Corp key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward